Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Amar Naik MD

Amar S. Naik MD

Founding Partner and Director, Inflammatory Bowel Disease Program, Midwest Digestive Health & Nutrition, Des Plaines, Illinois

Amar Naik is a board-certified gastroenterologist and medical director of the Inflammatory Bowel Disease program as well as a Founding Partner of Midwest Digestive Health & Nutrition www.mdhngi.com in DesPlaines, IL. He graduated from the University of Illinois College of Medicine at Chicago, and his postgraduate training was in Milwaukee at the Medical College of Wisconsin. Dr. Naik is an active member of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the Crohn’s and Colitis Foundation. He is devoted to multifaceted aspects of IBD patients’ care through development of a multidisciplinary clinical program to *Improve access to high quality care, *Maintain longterm treatment efficacy with high health related quality of life, and *Perform research with a goal to improve IBD treatment outcomes in unique patient populations. Dr. Naik has presented his research in international GI meetings as well as published in peer-reviewed journals in the field of Gastroenterology. Additionally, he has a special interest in IBD education, with involvement in physician and patient education programs.

Disclosures

Dr. Naik is on the speakers' bureaus for Abbvie, Takeda, Pfizer, and Bristol Meyers Squibb.

Recent Contributions to PracticeUpdate:

  1. Association Between Statin Use and Inflammatory Bowel Diseases
  2. Adalimumab Treatment After Complete Resolution of Sepsis and Abscess in Patients With Crohn's Disease
  3. Discontinuation of Infliximab and Risk of Relapse in Patients With Sustained Complete Remission of Crohn’s Disease
  4. Patient Outcomes With Early vs Late Use of Vedolizumab in Ulcerative Colitis
  5. Head-to-Head Comparison of Ustekinumab and Adalimumab in the Treatment of Moderate to Severe Crohn's Disease
  6. Discontinuing Infliximab in Patients With Ulcerative Colitis in Remission
  7. Deep Neural Network Accurately Predicts Prognosis of Ulcerative Colitis Using Endoscopic Images
  8. Risk of Venous Thromboembolism After Hospital Discharge in Patients With IBD
  9. Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis
  10. Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications

Most Read This Week

Recently Updated